Abstract
We evaluated the efficacy of ovarian suppression with a GnRH agonist in the treatment of women with prospectively confirmed menstrual-related mood disorders (MRMD) during a double-blind, placebo-controlled, parallel design trial. All women (patients and controls) received either GnRH agonist (depot leuprolide acetate) or placebo (N saline) IM every four weeks for 24 weeks and received in random sequence estradiol and progesterone as “add back” hormones during the latter 12 weeks. ANOVA-R was employed to examine the effects of depot lupron in women with MRMD compared with placebo and compared to controls.
ANOVA-R demonstrated significant improvements in MRMD symptoms after two months in the women receiving active depot lupron compared with symptoms at baseline and during placebo treatment. A reappearance of significant mood and behavioral symptoms was experienced by several women with MRMD, but none of the control women, during both estradiol and progesterone “add back” phases. We are presently attempting to determine whether the clinically significant mood and behavioral symptoms in women with MRMD during “add back” represents a re-emergence of typical symptom cyclicity or gonadal steroid-induced affective state changes.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schmidt, P., Rubinow, D. Role of Gonadal Steroids in MRMD. Neuropsychopharmacol 11, 282 (1994). https://doi.org/10.1038/sj.npp.1380203
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.npp.1380203